These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19704160)

  • 21. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
    Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
    Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gefitinib (Iressa, ZD 1839) for non-small cell lung cancer (NSCLC): recents results and further strategies.
    Manegold C
    Adv Exp Med Biol; 2003; 532():247-52. PubMed ID: 12908563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy].
    Sun Y; Wu YL; Li LY; Liao ML; Jiang GL; Kim ES; Douillard JY; Milenkova T
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):377-80. PubMed ID: 21875470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Approved use of gefitinib.
    Lyle J
    Am J Health Syst Pharm; 2004 Oct; 61(19):2008; author reply 2008. PubMed ID: 15509120
    [No Abstract]   [Full Text] [Related]  

  • 25. [Gefitinib in non-small cell lung cancer].
    Nakagawa K
    Nihon Rinsho; 2004 Jul; 62(7):1312-20. PubMed ID: 15283149
    [No Abstract]   [Full Text] [Related]  

  • 26. Updated data from the Iressa survival in lung cancer trial.
    Tyagi P
    Clin Lung Cancer; 2005 May; 6(6):340-2. PubMed ID: 15943893
    [No Abstract]   [Full Text] [Related]  

  • 27. Gefitinib in patients with non-small cell lung cancer: symptomatic improvement within a few days.
    Bearz A; Vaccher E; Spazzapan S; Berretta M; Tirelli U
    Lung Cancer; 2005 Sep; 49(3):417-8. PubMed ID: 16102608
    [No Abstract]   [Full Text] [Related]  

  • 28. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
    Kim ES; Hirsh V; Mok T; Socinski MA; Gervais R; Wu YL; Li LY; Watkins CL; Sellers MV; Lowe ES; Sun Y; Liao ML; Osterlind K; Reck M; Armour AA; Shepherd FA; Lippman SM; Douillard JY
    Lancet; 2008 Nov; 372(9652):1809-18. PubMed ID: 19027483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
    Park K; Goto K
    Curr Med Res Opin; 2006 Mar; 22(3):561-73. PubMed ID: 16574039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gefitinib therapy for non-small cell lung cancer.
    Birnbaum A; Ready N
    Curr Treat Options Oncol; 2005 Jan; 6(1):75-81. PubMed ID: 15610717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
    Johnson DH; Arteaga CL
    J Clin Oncol; 2003 Jun; 21(12):2227-9. PubMed ID: 12748243
    [No Abstract]   [Full Text] [Related]  

  • 32. Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
    Vansteenkiste J
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):5-17. PubMed ID: 14748652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Singh N; Aggarwal AN
    Lancet; 2009 Feb; 373(9663):541-2; author reply 542. PubMed ID: 19217980
    [No Abstract]   [Full Text] [Related]  

  • 34. Gefitinib in the treatment of advanced non-small-cell lung cancer.
    Reck M
    Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer.
    Cersosimo RJ
    Am J Health Syst Pharm; 2004 May; 61(9):889-98. PubMed ID: 15156965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC).
    Bearz A; Fratino L; Spazzapan S; Berretta M; Giacalone A; Simonelli C; Tirelli U
    Lung Cancer; 2007 Jan; 55(1):125-7. PubMed ID: 17064811
    [No Abstract]   [Full Text] [Related]  

  • 37. Significance of the papillary subtype in relation to durable response to gefitinib in advanced non-small cell lung cancer.
    Garfield DH
    Lung Cancer; 2006 Nov; 54(2):259. PubMed ID: 16935393
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer.
    Wang MZ; Li LY; Wang SL; Zhang XT; Zhong W; Zhang L
    Chin Med J (Engl); 2006 Jan; 119(1):63-8. PubMed ID: 16454984
    [No Abstract]   [Full Text] [Related]  

  • 39. [Development of individualized therapy of non-small cell lung cancer targeted at the EGF receptor].
    Kakiuchi S; Yano S; Sone S
    Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1831-8. PubMed ID: 16223143
    [No Abstract]   [Full Text] [Related]  

  • 40. [Advanced lung cancer of performance status 3 successfully treated by gefitinib--a case report].
    Kambayashi T; Ishibashi O; Yanagihara K; Tanaka F; Hasegawa S; Wada H
    Gan To Kagaku Ryoho; 2004 Feb; 31(2):223-6. PubMed ID: 14997756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.